IGF1R and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, studies from our lab and others' have demonstrated the contributions of IGF-IR signaling to the pathogenesis of other hematological neoplasms, including T-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and CML [20–24, 65].